Effect of soluble vascular endothelial growth factor receptor-1 on atherosclerotic plaque

doi:10.3969/j.issn.2095-4344.2016.18.017

Abstract

Abstract:

BACKGROUND: Angiogenesis in atherosclerotic plaque occurred on the basis of atherosclerotic lesions, and the new formed blood vessels promoted the development of angiogenesis. Soluble vascular endothelial growth factor receptor 1 (sFlt-1) gene transfection reduces neointimal formation after vascular injury in rabbits, also reduces early vascular inflammation and proliferation, and the formation of neointima lately.

OBJECTIVE: To observe the effects of highly expressed sFlt-1 on atherosclerotic plaque.

METHODS: A total of 48 male New Zealand rabbits were divided into four groups randomly: normal control group (n=8), sham operation group (n=8), balloon injury+high lipid diet+pEGFP-N1 group (n=16) and balloon injury+high lipid diet+pEGFP-N1-sFlt-1 group (n=16). Normal control group and sham operation group were supplied with normal diet. Balloon injury+high lipid diet+pEGFP-N1 group and balloon injury+high lipid diet+pEGFP-N1-sFlt-1 group were supplied with high lipid diet and injured by balloon 2 weeks later. Balloon injury+high lipid diet+pEGFP-N1 group was transfected with pEGFP-N1 and balloon injury+high lipid diet+pEGFP-N1-sFlt-1 group was transfected with pEGFP-N1-sFlt-1.

RESULTS AND CONCLUSION: In the balloon injury+high lipid diet+pEGFP-N1 group and balloon injury+high lipid diet+pEGFP-N1-sFlt-1 group, blood lipid levels apparently increased. At 3 days after model establishment, sFlt-1 expression levels noticeably increased, and atherosclerotic plaque formed to different degrees. Plaque area, plaque perimeter, plaque maximum thickness and the number of positive-cells within the plaque were significantly less in the balloon injury+high lipid diet+pEGFP-N1-sFlt-1 group than in the balloon injury+high lipid diet+pEGFP-N1 group. These results confirm that sFlt-1 gene may express effectively in iliac artery wall of rabbit, inhibited the formation of atherosclerotic plaque and delayed the development of atherosclerotic plaque.
中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Key words: Receptors, Vascular Endothelial Growth Factor, Atherosclerosis, Transfection, Tunica Intima.

Zhou Yi-hua, Wang Shu, Yuan Ying. Effect of soluble vascular endothelial growth factor receptor-1 on atherosclerotic plaque[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(18): 2697-2702.

Figures/Tables 5

References

[1] Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1): 9-22.

[2] Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998;98(20):2108-2116.

[3] Wolf M, Kettyle E, Sandler L, et al. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol. 2001;98(5 Pt 1):757-762.

[4] Zolota V, Gerokosta A, Melachrinou M, et al. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast. Anticancer Res. 1999;19(4B):3269-3274.

[5] Celletti FL, Hilfiker PR, Ghafouri P, et al. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol. 2001;37(8):2126-2130.

[6] Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417(6890):750-754.

[7] Hoefer IE, Timmers L, Piek JJ. Growth factor therapy in atherosclerotic disease-friend or foe. Curr Pharm Des. 2007;13(17):1803-1810.

[8] 苏航,王蒨,米宏志,等.99Tcm-3PEG4-RGD用于家兔易损斑块分子显像[J].中国医学影像技术,2014,30(6):813-817.

[9] 刘俊田.动脉粥样硬化发病的炎症机制的研究进展[J].西安交通大学学报(医学版).2015,36(2):141-152.

[10] Di Marco GS, Kentrup D, Reuter S, et al. Soluble Flt-1 links microvascular disease with heart failure in CKD. Basic Res Cardiol. 2015;110(3):30.

[11] Youssry I, Makar S, Fawzy R, et al. Novel marker for the detection of sickle cell nephropathy: soluble FMS-like tyrosine kinase-1 (sFLT-1). Pediatr Nephrol. 2015. in press.

[12] Zhu H, Li Z, Mao S, et al. Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice. Cancer Gene Ther. 2011;18(12):884-896.

[13] Hagmann H, Bossung V, Belaidi AA, et al. Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination. PLoS One. 2014;9(1):e85258.

[14] Zhai YL, Zhu L, Shi SF, et al. Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy. PLoS One. 2014;9(7):e101779.

[15] Shibuya M. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases. Endocr Metab Immune Disord Drug Targets. 2015;15(2):135-144.

[16] Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99(13):1726-1732.

[17] Wahl ML, Kenan DJ, Gonzalez-Gronow M, et al. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem. 2005;96(2):242-261.

[18] Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349(24):2316-2325.